Oxford Immunotec and Lophius Biosciences Sign Licensing and Collaboration Agreement
29 Jan 2013Oxford Immunotec, a medical diagnostic company developing tests in the fields of infectious and immunological disease and Lophius Biosciences, a leader in the field of novel T-cell based diagnostic test systems, announced today that the companies have signed agreements under which both companies will have access to certain intellectual property from the other party. Oxford Immunotec will be able to develop and commercialize novel T-cell based assays using Lophius´ proprietary UREA technology in certain territories. Lophius Biosciences will be able to develop and commercialize novel T-cell based assays under a license to Oxford Immunotec's proprietary T-SPOT® technology.
Dr. Peter Wrighton-Smith, Chief Executive Officer, Oxford Immunotec commented: “We believe that Lophius’s UREA technology has distinct advantages over conventional methods of designing and producing antigens for T-cell based diagnostic test systems. We are looking forward to combining Lophius’s technology with our own, to develop and launch innovative new assays for infectious and immunological disease”.
“We are very pleased with this partnership with Oxford Immunotec, a leading company in the development of T-cell based assays, which provides us access to the T-SPOT® technology. This cooperation also confirms the commercial potential of our proprietary UREA technology platform which led to recent successful development of two CE-marked tests, namely T-Track® CMV and T-Track® EBV.” said Dr. Michael Lutz, Managing Director of Lophius Biosciences.
Related Products
Request Quote for All Products
T-SPOT®.TB
Oxford ImmunotecThe T-SPOT®.TB test is a revolutionary product that diagnoses both latent TB infection and active disease by measuring T cells that have been specifically activated by Mycobacterium tuberculosis (MTB) antigens. The T-SPOT.TB test sets new clinical standards of sensitivity and reliability. The product was licensed across Europe in July 2004 and received FDA premarket approval in July 2008. It has been designed to replace the current tuberculin skin test (Mantoux test), bringing effective TB testing to many new patient groups where the skin test gives poor or unreliable results. This revolutionary technology has been tested in many thousands of patients in all parts of the world. Studies have shown the excellent sensitivity and specificity of the T-SPOT.TB test and demonstrate its utility for the diagnosis and control of TB. The T-SPOT.TB kit is supplied with a plate containing 12 X 8 well strips. 4 wells are required for each patient sample